SOURCE: Antisense Therapeutics Limited

October 23, 2007 11:28 ET

Antisense Therapeutics to Present at Rodman & Renshaw 9th Annual Healthcare Conference

MELBOURNE, AUSTRALIA--(Marketwire - October 23, 2007) - Antisense Therapeutics Limited (ASX: ANP) today announced that the Company is scheduled to present at the Rodman & Renshaw 9th Annual Global Healthcare Conference, on November 5-7, in New York City.

Mark Diamond, Antisense Therapeutics Chief Executive Officer, will give a presentation on November 7, at 8:50 a.m. EST on the Company and its lead compound, ATL1102, which is currently in Phase IIa clinical trials as a treatment for multiple sclerosis (MS). The presentation will be followed by a question and answer session and a live webcast may be accessed at the Company's website, www.antisense.com.au, or at http://wsw.com/webcast/rrshq12/anp.au.

A replay of the presentation will be archived for 90 days after the conference, at the same locations. For more information about the Rodman & Renshaw 9th Annual Healthcare Conference, please visit Rodman & Renshaw's website at www.rodmanandrenshaw.com.

Antisense management will be available for meetings in New York on November 7-9.

The Company's current Phase IIa trial is a study in 80 patients to assess the safety and efficacy of ATL1102 as a treatment for relapsing remitting MS.

ATL1102 is a second-generation antisense inhibitor of CD49d, a subunit of VLA-4 (Very Late Antigen-4). It is believed that the inhibition of VLA-4 prevents white blood cells from entering sites of inflammation, thereby halting the progression of inflammatory diseases such as MS. VLA-4 is a clinically validated target in the treatment of MS. Antisense inhibition of VLA-4 has demonstrated positive effects in an animal model of MS and the data has been published - Myers et al., J Neuroimmunol 160, 12-24 (2005).

About Antisense Therapeutics Limited

Antisense Therapeutics Limited (ASX: ANP) is an Australian publicly listed biopharmaceutical drug discovery and development company. Its mission is to create, develop and commercialise novel antisense pharmaceuticals for large unmet markets. ANP's major shareholders include Circadian Technologies Limited (ASX: CIR) and Antisense Therapeutics' strategic technology partner, Isis Pharmaceuticals Inc.

Website: www.antisense.com.au

Contact Information

  • Contact Information

    US Investors:
    Andrea Costa
    The Global Consulting Group
    (646) 284-9461
    acosta@hfgcg.com

    Company:
    Mark Diamond
    Managing Director
    +61 3 9827 8999